SevenBridge Financial Group LLC Sells 2,204 Shares of AbbVie Inc. $ABBV

SevenBridge Financial Group LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,487 shares of the company’s stock after selling 2,204 shares during the period. SevenBridge Financial Group LLC’s holdings in AbbVie were worth $3,612,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $26,000. Caitlin John LLC bought a new position in AbbVie during the 3rd quarter valued at approximately $33,000. Financial Gravity Companies Inc. purchased a new position in AbbVie during the second quarter valued at $36,000. Delos Wealth Advisors LLC purchased a new position in AbbVie during the second quarter valued at $39,000. Finally, Redmont Wealth Advisors LLC bought a new stake in AbbVie in the third quarter worth $41,000. Institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $260 price target, highlighting that AbbVie’s Skyrizi and Rinvoq growth story is still in early stages — a clear vote of confidence that can support multiple expansion. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: AbbVie reported promising Phase 1 results for ABBV‑295 (topline), which supports pipeline optionality and future upside if early signals translate into later‑stage success. Clinical progress tends to underpin biotech valuations. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: Sector commentary from prominent investors (e.g., Josh Brown) frames large-cap biotech as resilient growth exposure, which can lift sentiment toward blue‑chip names like AbbVie even amid mixed news. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Analysis shows the narrative on AbbVie’s immunology franchise is shifting: fair‑value models are largely unchanged and analysts remain split between upside from immunology/pipeline and competition risk — a balanced view that may cap volatility. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: AbbVie’s Leerink conference presentation (transcript) provides investor access to management’s outlook and pipeline detail — useful for fine‑tuning models but not market moving by itself. AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies point to a larger addressable market for psychiatric/neurology assets — a longer‑term tailwind if AbbVie advances relevant programs. Bipolar Depression Market Expected to Witness Accelerated Expansion
• Negative Sentiment: Clinical competition: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis, a direct competitive setback that could pressure pricing and market share for Skyrizi in a key indication. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Reported insider selling coincided with a near‑term share dip, a classic negative signal for momentum traders even if fundamentals remain intact. AbbVie (NYSE:ABBV) Stock Price Down 1% on Insider Selling
• Negative Sentiment: Governance/watchlist noise: CEO Robert Michael received a sizable pay increase, which can attract short‑term criticism from income/ESG investors and amplify negative headlines. AbbVie’s Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO

AbbVie Stock Up 0.3%

Shares of ABBV opened at $227.58 on Thursday. The business has a 50-day simple moving average of $224.58 and a two-hundred day simple moving average of $224.47. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market cap of $402.40 billion, a price-to-earnings ratio of 96.43, a PEG ratio of 0.79 and a beta of 0.34.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ABBV. UBS Group cut their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday. Citigroup reduced their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.